Skyhawk Therapeutics Advances Global Phase 2/3 HD Trial
BOSTON, Mass. — July 14, 2026 Skyhawk Therapeutics, Inc. has announced a major expansion of its global pivotal Phase...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology oncology innovation Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine targeted therapy
BOSTON, Mass. — July 14, 2026 Skyhawk Therapeutics, Inc. has announced a major expansion of its global pivotal Phase...
IRVING, Texas — July 14, 2026 Caris Life Sciences has expanded its precision oncology portfolio with the launch of...
SANTA CLARA, Calif., June 2, 2026 Agilent Technologies announced that the U.S. Food and Drug Administration (FDA) has approved...
BASEL, Switzerland – May 7, 2026 Roche announced it has entered into a definitive merger agreement to acquire PathAI,...
Palo Alto, USA | April 30, 2026 Guardant Health and Nuvalent have announced a multi-year strategic collaboration to develop...
MELBOURNE, Australia; INDIANAPOLIS, United States — December 22, 2025 — Telix Pharmaceuticals Limited has reported a major precision medicine...
